The new year is approaching, and domestic and foreign pharmaceutical companies such as Novartis and Conba have dumped their assets!

Since November, many pharmaceutical companies have made the decision to sell assets and transfer shares, including domestic pharmaceutical companies such as Kang En Bay, Renfu Pharmaceutical, Dongyang Sunshine, Laimei Pharmaceutical, Jinghua Pharmaceutical, and large multinational pharmaceutical companies such as Novartis.

.
The "selling" of these pharmaceutical companies has a certain relationship with the company's sluggish performance and focus on the main business
.
Conba: Listed for the transfer of 25% of Deer Pharmaceuticals.
On November 29, news, Zhejiang Conba Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Conba") issued an announcement stating that it would publicly transfer 25% of Deer Pharmaceuticals.
Equity
.
The announcement shows that the sale is mainly to focus on the development of the company's core business in the traditional Chinese medicine health industry, and to promptly dispose of inefficient assets and withdraw funds
.
It is worth mentioning that this is the fourth holding company's equity transferred by the company in half a year
.
On June 12, Conba announced that it planned to transfer its 30% stake in Lanxi Lanxin Microfinance Co.
, Ltd.
through the Zhejiang Equity Exchange.
On August 13, Conba announced that the board of directors agreed to the company.
Transferring 100% equity of Guizhou Beite Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Equity Exchange; on September 23, the company announced that it intends to transfer its holdings of Jiangxi Zhenshiming Pharmaceutical Co.
, Ltd.
through public listing in Zhejiang Equity Exchange.
42% equity of the company
.
It is understood that the company's performance is sluggish.
In the first three quarters of 2021, the company's net profit dropped by 60.
52% from the same period last year to 215 million yuan
.
Renfu Medicine: plans to transfer about 2.
52% of Huatai Insurance's shares held by the company.
Renfu Medicine announced on the evening of November 19 that the company and Anda North America signed the "Share Transfer Agreement" on November 19, 2021, and intends to transfer to it The company holds about 2.
52% of Huatai Insurance at a transfer price of approximately RMB 1.
026 billion
.
Dongyang Sunshine: intends to transfer the company’s 452 million shares of Dongyang Sunshine Pharmaceuticals.
On the evening of November 11, Dongyang Sunshine announced that the company intends to transfer the company to Guangdong Dongyang Sunshine Pharmaceutical Co.
, Ltd.
and its wholly-owned subsidiary, Hong Kong Dongyang Sunshine Sales Co.
, Ltd.
The total shares held by Dongyang Sun Pharmaceuticals total 452 million shares, accounting for approximately 51.
41% of Dongyang Sun Pharmaceuticals’ total share capital, and the transaction price is 3.
723 billion yuan.

.
Jinghua Pharmaceutical: Sale of shares in its subsidiary company On November 4, Jinghua Pharmaceutical issued an announcement stating that it had recently completed the sale of shares in its subsidiary Wannianchang Pharmaceutical
.
Upon notification from Nantong Public Resources Trading Center, the transferee of the equity is Jiangsu Qichen New Materials Co.
, Ltd.
, and the transaction amount is approximately RMB 6,940
.
Novartis: Sale of Roche's equity In early November, the pharmaceutical giant Novartis also announced that the company and Roche signed a $20.
7 billion transaction agreement to sell Roche's shares acquired since 20 years ago to the other side
.
It is understood that Novartis became a Roche shareholder in 2001 and spent US$2.
8 billion in cash to acquire 20% of Roche’s shares, or 32 million shares, at US$87 per share
.
Novartis currently holds 53.
3 million bearer ordinary shares of Roche, which accounts for about 1/3 of Roche's total bearer shares issued
.
According to this agreement, Novartis will sell its shares at a price of US$388.
99 per share
.
It is reported that Novartis will benefit approximately US$14 billion from the sale of shares
.
From the perspective of the industry, it is not new for pharmaceutical companies to start a "sell, sell" model.
In recent years, the market structure under the medical reform has changed.
Pharmaceutical companies sell non-core assets, which is conducive to the sustainable development of enterprises
.
"To revitalize funds, solve current difficulties, and focus on R&D investment in core products is also the country's goal for the concentrated and healthy development of the pharmaceutical industry
.
"